News Category
Regentis Biomaterials is advancing GelrinC, an off-the-shelf hydrogel implant designed to regenerate knee cartilage, as an FDA-authorized pivotal tria...
American Fusion's Texatron fusion program has moved into active testing, achieving record pressures and attracting new analyst coverage, signaling a c...
The 2026 Disruptive Growth & Life Sciences Conference, organized by Moody Capital Solutions, is set to connect investors with emerging and under-cover...
SuzieQ Holdings Inc. is set to participate in the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference, highlighting its role in ...
A new study shows that treating certain ER patients while seated, rather than waiting for a bed, significantly cuts wait times, potentially lowering h...
Helus Pharma's completion of enrollment in its pivotal Phase 3 trial for HLP003 marks a significant step toward a potential new treatment for major de...
Helus Pharma's appointment of seasoned biopharma executive Michael Halstead as CEO signals a strategic shift toward commercialization as the company a...
Ocumetics Technology Corp. has completed the second tranche of its private placement, securing $2.5 million to support its first-in-human clinical tri...
VERAXA Biotech AG shareholders approved proposals with over 99.94% support, enhancing corporate flexibility for growth and development of its oncology...
VERAXA Biotech AG announced the advancement of its bispecific antibody-drug conjugate program VXA-222 after OmniAb completed discovery work, moving th...
Gerresheimer starts operations at a new, sustainable plant in Zhenjiang Dagang, China, doubling its capacity for glass primary packaging for injectabl...
Darwin AG has changed its name to Novogenia AG, aligning its corporate identity with its core operating brand to enhance market visibility and support...
NanoViricides is progressing its oral gummies formulation of NV-387 toward a Phase II clinical trial for the Bundibugyo ebolavirus outbreak in the Dem...
Redwood AI Corp. has been added to the CSE25 Index, reflecting its growth in AI-driven chemistry and drug development, which may increase its attracti...
Helus Pharma announced fiscal 2026 financial results and progress on its Phase 3 trial for HLP003 in major depressive disorder, with topline data expe...
Quantum BioPharma Ltd. is featured in a BioMedWire editorial highlighting the need for new MS treatments and its drug candidate Lucid-MS, which aims t...
The article highlights how advanced drug delivery technologies, such as Oncotelic Therapeutics' Deciparticle platform, are gaining traction as a cost-...
Quantum BioPharma is progressing its first-in-class drug candidate Lucid-MS, which directly protects the myelin sheath in multiple sclerosis, toward P...
VERAXA Biotech announced new in vitro data validating its BiTAC-ADC platform, which selectively targets cancer cells while minimizing toxicity, and pl...
Redwood AI Corp. develops AI-powered platforms to accelerate chemistry research and development across pharmaceutical, defense, public safety, and ind...
NanoViricides has received approval from the Democratic Republic of Congo's Pillar Committee to proceed with a Phase II clinical trial of NV-387 Oral ...
Helus Pharma announced that its Chief Medical Officer will present at a key industry conference, highlighting the company's progress in developing nov...
Onco-Innovations Limited has initiated process development and scale-up for ONC010, a key step toward IND-enabling studies and first-in-human trials f...
Quantum BioPharma's Lucid-MS program aims to address the unmet need for therapies that protect or restore myelin in multiple sclerosis, with phase 1 s...
NeuroOne Medical Technologies will present at the Planet MicroCap Las Vegas 2026 Conference on June 17, 2026, providing updates on its OneRF platform ...
GeoVax CEO David Dodd comments on recent pharmaceutical acquisitions that signal a strategic shift toward vaccine innovation, health security, and inf...
Quantum BioPharma's lead drug candidate Lucid-MS targets nerve damage in multiple sclerosis, with an upcoming Phase 2 trial, while its commercial prod...
Helus Pharma's participation in the Jefferies Global Healthcare Conference underscores its advancing clinical programs for depression and anxiety, wit...
TransCode Therapeutics has started a Phase 2a trial of TTX-MC138 in colorectal cancer patients with minimal residual disease, aiming to reduce recurre...
NanoViricides announces that its broad-spectrum antiviral candidate NV-387 warrants evaluation for the Bundibugyo Ebola outbreak, offering potential a...
SureNano Science Ltd. is advancing GEP-44, a patented GLP-1 peptide for obesity and metabolic disorders, positioning itself as an agile entrant in the...
Oncotelic Therapeutics, a small biotech firm, has integrated 28 million scientific abstracts into its proprietary AI platform, positioning itself to c...
Peer-reviewed preclinical data published in Advances in Redox Research shows Telomir-Zn improves survival, reduces oxidative stress, and lowers hepati...
Lantern Pharma announced that the FDA raised no objections to proposed protocol amendments for its Phase 2 HARMONIC trial, providing a clearer regulat...
NanoViricides emphasizes the potential of its oral drug candidate NV-387 for pandemic preparedness amid the Bundibugyo Ebola outbreak, targeting commo...
Quantum BioPharma announced that its collaborative multiple sclerosis imaging study with Massachusetts General Hospital has reached midpoint enrollmen...
LIXTE Biotechnology Holdings announced first-quarter 2026 progress on its lead oncology candidate LB-100, including expansion of its ovarian cancer tr...
Dogwood Therapeutics announced strong operational progress in Q1 2026, including enrollment of 164 patients in its Halneuron Phase 2b CINP study with ...
Innovations in bypassing the blood-brain barrier, such as Oncotelic's intranasal nose-to-brain system, are poised to transform CNS drug delivery, addr...
Silo Pharma announced a strategic initiative to develop ibogaine-based therapeutics for traumatic brain injury and related neuropsychiatric conditions...
Three fatalities on a cruise ship linked to hantavirus highlight the risks of this rare infection and the importance of diagnostic systems like those ...
NanoViricides announces FDA Orphan Drug Designation for NV-387 against measles, offering incentives and supporting regulatory advancement amid rising ...
VolitionRx's successful detection of nucleosomes in capillary blood from sepsis patients using a finger-prick prototype marks a step toward point-of-c...
Helus Pharma collaborates with TARA Mind and VETS to enhance veteran participation in its Phase 3 major depressive disorder trial, leveraging networks...
Ventripoint's strategic partner Lishman Global has submitted the VMS+™ 4.0 system to China's NMPA under an expedited green channel, potentially accele...
Formycon AG will publish its FY 2025 results on April 22, 2026, and host a conference call, while also outlining its participation in several internat...
Helus Pharma announces the appointment of Dr. Ken Kramer as senior vice president of medical affairs, bringing over 20 years of neuroscience leadershi...
GeoVax Labs announced its 2025 financial results and plans to start a pivotal Phase 3 trial for its GEO-MVA mpox/smallpox vaccine in the second half o...
